

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imricor Medical Systems, Inc.
ARBN	633 106 019

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Mark Tibbles
Date of last notice	28 March 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	17 June 2022

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<ul style="list-style-type: none"> - 2,615,305 shares of Class A common stock (equivalent to 2,615,305 CHESS Depositary Interests) - 2,141,573 CHESS Depositary Interests (equivalent to 2,141,573 shares of Class A common stock) - 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 100,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 71,010 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 40,896 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Class	Class A Common Stocks
Number acquired	107,253
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash. Deemed issue price of US\$0.373 per security.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> - 2,722,558 shares of Class A common stock (equivalent to 2,722,558 CHESS Depositary Interests) - 2,141,573 CHESS Depositary Interests (equivalent to 2,141,573 shares of Class A common stock) - 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 100,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 71,010 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 40,896 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue under ESOP as approved at AGM on 4 May 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.